Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …
is clinically heterogeneous: 40% of patients respond well to current therapy and have …
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase …
Background Drug treatments for patients with high-risk myelodysplastic syndromes provide
no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall …
no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall …
[HTML][HTML] Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
JC Byrd, RR Furman, SE Coutre, IW Flinn… - … England Journal of …, 2013 - Mass Medical Soc
Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–…
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–…
Do outside directors monitor managers?: Evidence from tender offer bids
JW Byrd, KA Hickman - Journal of financial economics, 1992 - Elsevier
Examining 128 tender offer bids made from 1980 through 1987, we categorize outside directors
as either independent of or having some affiliation with managers, and find that bidding …
as either independent of or having some affiliation with managers, and find that bidding …
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
…, S Stilgenbauer, KR Rai, JC Byrd… - Blood, The Journal …, 2018 - ashpublications.org
The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute …
We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to
ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-…
ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-…
[HTML][HTML] Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
…, LZ Rassenti, J Powell, D Botstein, JC Byrd… - The Journal of …, 2001 - rupress.org
The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy
of mature B cells with a characteristic clinical presentation but a variable clinical course. …
of mature B cells with a characteristic clinical presentation but a variable clinical course. …
[HTML][HTML] ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
…, DS Neuberg, IW Flinn, KR Rai, JC Byrd… - … England Journal of …, 2004 - Mass Medical Soc
Background The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive
disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-…
disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-…
[HTML][HTML] Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
…, BY Chang, AJ Johnson, JC Byrd - … England Journal of …, 2014 - Mass Medical Soc
Background Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and …
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and …